The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Peer Review reports

Original Submission
8 Jun 2022	Submitted	Original manuscript
17 Aug 2022	Reviewed	Reviewer Report - Michel Shamy
29 Sep 2022	Reviewed	Reviewer Report
4 Nov 2022	Author responded	Author comments - Nicolas Bruder
Resubmission - Version 2
4 Nov 2022	Submitted	Manuscript version 2
Publishing
2 Dec 2022	Editorially accepted
20 Dec 2022	Article published	10.1186/s12883-022-03002-8

Back to article page